1. Useful information on rare diseases from an EU perspective. [Accessed 2022 Mar 12]. Available from: https://ec.europa.eu/health/ph_information/documents/ev20040705_rd05_en.pdf
2. Rare Disease Act of 2002, Pub. L. No. 107–280, 116 Stat. 1988 (2002). [Accessed 2022 Mar 12]. Available from: https://history.nih.gov/research/downloads/pl107-280.pdf
3. Hayashi S, Umeda T. 35 years of Japanese policy on rare diseases. Lancet. 2008;372(9642):889–90. https://doi.org/10.1016/S0140-6736(08)61393-8.
4. Broekhoff TF, Sweegers CCG, Krijkamp EM, Mantel-Teeuwisse AK, Leufkens HGM, Goettsch WG, et al. Early cost-effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) treatment for spinal muscular atrophy I in the Netherlands with relapse scenarios. Value Health. 2021;24(6):759–69. https://doi.org/10.0.3.248/j.jval.2020.09.021
5. Ana S, Jimmy L. Rare Diseases, Diagnosis, Therapies, and Hope. St. Louis, MO: Rare Genomics Institute. 2014;6. [Accessed 2022 Mar 12]. Available from: https://static1.squarespace.com/static/55899403e4b0dbf7728075b1/t/55db714de4b04e4d229c580d/1440444749559/Rare-Diseases-Book-Diagnosis-Therapies-and-Hope-V5-330b.pdf